Loading
Life sciences · Journal article
Frontiers in Oncology · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Traditional Chinese medicine (TCM) is incorporated into the long-term integrative management of advanced prostate cancer in China, but evidence linking treatment duration with survival remains limited. Because treatment duration accumulates during follow-up, classifying patients by their final recorded treatment duration can misallocate pre-threshold observation time and bias survival comparisons. Methods We evaluated the association between cumulative continuous TCM treatment exceeding 6 months and all-cause mortality in a single-center retrospective cohort of 242 patients with metastatic prostate adenocarcinoma at diagnosis who received continuous TCM from diagnosis. Follow-up continued through May 1, 2024. Treatment exceeding 6 months was modeled as a time-dependent exposure in Multivariable Cox regression, with sensitivity analyses addressing an alternative threshold, disease-severity adjustment, influential observations, and loss to follow-up. Results During follow-up, 147 deaths occurred. Median overall survival was 53.0 months (95% confidence interval [CI], 44.0–61.0), with 3- and 5-year survival rates of 64.0% and 43.4%, respectively. Cumulative continuous TCM treatment exceeding 6 months was associated with a lower average hazard of all-cause mortality (adjusted hazard ratio [HR], 0.269; 95% CI, 0.186–0.389; P < 0.001). The association attenuated over time: adjusted HRs at 1, 2, 3, and 5 years were 0.098, 0.192, 0.286, and 0.471, respectively. Sensitivity analyses yielded estimates in the same direction. Conclusion These findings define a duration-survival association among TCM users and support prospective, multicenter evaluation using detailed longitudinal treatment records.